C.G. is an 11-year-old boy (weight 45 kg) with asthma and allergies to pet dander and mold. Recently, C.G.’s asthma symptoms have worsened despite taking budesonide/formo- terol 160/4.5 mcg 2 puffs twice daily plus every 4–6 hours as needed for shortness of breath. His daytime asthma symp- toms are presenting about twice a month, and he is waking up on average twice a week. C.G. has no other risk factors for exacerbations. Adherence and appropriate inhaler tech- nique have been verified. He is referred to a pulmonologist for further treatment. Evaluation for type 2 inflammation reveals FeNO 20 ppb, IgE 250 IU/mL, and blood eosinophils 120 cells/mm3. PSAP 2023 Book 3 • Pulmonary and Gastrointestinal Diseases 23 Severe Asthma 5. 6. Which one of the following is best to recommend for C.G.? A. Omalizumab 300 mg subcutaneously every 4 weeks B. Benralizumab 30 mg subcutaneously every 4 weeks times 3 doses, then every 8 weeks C. Omalizumab 150 mg subcutaneously every 4 weeks D. Mepolizumab 100 mg subcutaneously every 4 weeks Which one of the following is the best education point to share with C.G. and his family? A. B. C. D. Subcutaneous biologic therapies are the only alternative therapy to ICS-LABA. Most biologic therapies can be self-administered after initial monitoring in the clinic. Anaphylaxis risk precludes patients from self- administering biologic therapy. Subcutaneous injection increases the risk of infection.
[Solved]: C.G. is an 11-year-old boy (weight 45 kg) with asthma a
Need help with your Respiratory & Gas Exchange case study or NCLEX preparation? Connect with a verified Nursing expert now.